Suchergebnisse - "Canham, Joanna"

PubPharm (5)

1

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

enthalten in: Blood | 2024

von Othman, J. | Potter, N. | Ivey, A. | +17

2

Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML

enthalten in: Blood | 2024

von Othman, J. | Potter, N. | Ivey, A. | +24

3

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Russell, N. | Wilhelm-Benartzi, C. | Othman, J. | +117

4

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS : the UK NCRI AML19 trial

enthalten in: Blood advances | 2023

von Othman, J. | Wilhelm-Benartzi, C. | Dillon, R. | +19

5

A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)

enthalten in: Health technology assessment (Winchester, England) | 2015

von Noble, S. | Nelson, A. | Fitzmaurice, D. | +14

1
[1]